Terms: = Bone cancer AND PAX3, MGC120382, 5077, ENSG00000135903, CDHS, MGC120383, HUP2, P23760, WS1, MGC120384, MGC134778, MGC120381 AND Clinical Outcome
3 results:
1. Improving Risk Stratification for Pediatric Patients with Rhabdomyosarcoma by Molecular Detection of Disseminated Disease.
Lak NSM; Voormanns TL; Zappeij-Kannegieter L; van Zogchel LMJ; Fiocco M; van Noesel MM; Merks JHM; van der Schoot CE; Tytgat GAM; Stutterheim J
Clin Cancer Res; 2021 Oct; 27(20):5576-5585. PubMed ID: 34285060
[TBL] [Abstract] [Full Text] [Related]
2. clinical and Cytogenetic Profiles of Rhabdomyosarcoma with bone Marrow Involvement in Korean Children: A 15-Year Single-Institution Experience.
Lee DH; Park CJ; Jang S; Cho YU; Seo JJ; Im HJ; Koh KN; Cho KJ; Song JS; Seo EJ
Ann Lab Med; 2018 Mar; 38(2):132-138. PubMed ID: 29214757
[TBL] [Abstract] [Full Text] [Related]
3. Rhabdomyosarcoma: molecular diagnostics of patients classified by morphology and immunohistochemistry with emphasis on bone marrow and purged peripheral blood progenitor cells involvement.
Krsková L; Mrhalová M; Sumerauer D; Kodet R
Virchows Arch; 2006 Apr; 448(4):449-58. PubMed ID: 16365729
[TBL] [Abstract] [Full Text] [Related]
